An experimental gene-editing therapy that aims to lower bad cholesterol for the long-term after a single infusion is off to a ...

A one-time gene-editing infusion kept cholesterol levels low for a year, offering a potential new approach to preventing ...

Urnov is a professor of molecular therapeutics at the University of California, Berkeley, and a director at its Innovative Genomics Institute. In May, news broke of a biomedical first: the on-demand ...

Like countless Americans urged to take medicine every day to control high cholesterol, University of Pennsylvania cardiologist Kiran Musunuru frequently forgets to take his pills. But unlike most ...

Eli Lilly (LLY) announced that its gene editing candidate VERVE-102, added from its $1.3B acquisition of Verve Therapeutics last year, caused up to a 62% average decline in low-density lipoprotein ...

Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it acquired from Verve Therapeutics, with the candidate now showing strong and consistent cholesterol ...

“GLP-1 medicines have changed what is possible in obesity and Type 2 diabetes," Dr. Harith Rajagopalan said.

A UCSF team has submitted an application to the FDA seeking approval for a small trial of in utero gene therapy for a rare ...

A planned first-in-human trial aims to treat GM1 gangliosidosis in utero, possibly laying the foundation for prenatal gene ...

Dr. Jinsy Andrews, director of NYU Langone’s ALS Center, stopped by NY1 on Wednesday and got straight into how treatment for ...